Original Source(s)
Related Content
Rare Skin Reaction Reported With Tirzepatide
A single case report described possible lichen planus pigmentosus inversus following tirzepatide initiation.
May 7, 2026
-
3 min
FDA Expands Guselkumab Label in PsA
Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.
May 29, 2026
-
2 min
Dupilumab Gains Pediatric CSU Approval
Targets type 2 inflammation in a population with limited treatment options
April 24, 2026
-
2 min